In a groundbreaking advancement that could rewrite the therapeutic landscape of acute myeloid leukemia (AML), researchers at The Jackson Laboratory (JAX) for Genomic Medicine have unveiled a novel strategy to reactivate silenced tumor-suppressor genes within leukemia cells. Unlike traditional approaches that aim to eradicate cancer cells through toxic chemotherapy, this innovative method focuses on reversing gene silencing, thereby restoring the cell’s inherent ability to restrain malignant growth.
The crux of this research centers on the tumor-suppressor gene ZBTB7A, which in AML is not mutated or damaged but epigenetically switched off. This gene’s silencing allows leukemia cells to maintain their aggressive and immature state, contributing to disease persistence and resistance to treatment. By illuminating this epigenetic mechanism through advanced molecular tools, the team has paved the way for therapies that coax cancer cells back to a more controlled and differentiated state, attenuating their malignancy without collateral damage to healthy cells.
Epigenetics represents the study of gene activity regulation independent of changes to the DNA sequence itself. These changes involve intricate modifications to chromatin structure or RNA interactions that effectively mute or amplify particular genes’ expression patterns. Conventional DNA sequencing techniques primarily detect mutations within the genetic code but fall short of revealing such epigenetic silencing. Consequently, much of the complexity behind gene regulation in cancers remains obscured, presenting a significant obstacle in the development of targeted therapies.
To overcome these limitations, scientists led by Assistant Professor Eric Wang engineered an unprecedented tool combining CRISPR gene-editing precision with fluorescent in situ hybridization imaging, termed FISHnCRISP. This technology allows researchers to map the on-and-off states of genes directly within individual cells, providing an unprecedented view of the dynamic epigenetic environment inside leukemia cells. Employing FISHnCRISP, they identified that ZBTB7A is silenced through a sophisticated regulatory mechanism involving an elongated 3’ untranslated region (UTR) that attracts the RNA-binding protein ZFP36L2, suppressing the gene’s expression.
Further investigation revealed the involvement of lysine demethylase 4 (KDM4) enzymes in restructuring the chromatin landscape in AML cells, effectively condensing the DNA around ZBTB7A and switching off its activity. KDM4 enzymes remove methyl groups from histones, proteins around which DNA is wound, which in turn influences gene accessibility and transcriptional activity. Importantly, disturbing this epigenetic repressive complex offers a potentially druggable target to reactive silenced tumor suppressor genes.
Using patient-derived AML cells transplanted into mouse models to closely mimic human disease conditions, the research team tested inhibitors of KDM4 enzymes. Remarkably, blocking these enzymes led to the restoration of ZBTB7A expression, resulting in a significant reduction of leukemic burden. Notably, inhibiting KDM4 did not compromise normal hematopoiesis, highlighting the therapeutic index where malignant cells can be targeted specifically with minimal harm to normal blood formation processes.
The therapeutic implications of these findings are profound. AML cells characteristically arrest in an immature and stem cell-like state, which promotes unchecked proliferation and shields them from natural cell death pathways. Reactivating ZBTB7A using epigenetic inhibitors coerces these cells to resume differentiation into white blood cells, thereby increasing their vulnerability and reducing their pro-inflammatory, cancer-promoting signaling milieu. This mode of therapy reflects a paradigm shift from targeting cancer cells for destruction to reprogramming them toward natural cellular fates that suppress tumor growth.
“It’s analogous to restoring the brakes on a car that has lost control,” said Eric Wang. “Instead of unleashing toxic agents that indiscriminately kill cells, we aim to restore the molecular mechanisms that keep cancer cells in check, pushing them toward differentiation and eventual elimination.” Such differentiation therapy could dramatically reduce the side effects associated with conventional chemotherapy, offering a gentler yet potentially more effective treatment modality for AML patients.
Beyond AML, the techniques developed in this study have broad potential to explore epigenetic gene regulation in a variety of diseases where gene silencing plays a critical role. The combination of gene-editing and live-cell imaging is poised to revolutionize biomedical research by exposing the complex regulatory networks that govern cellular behavior. This could enable the discovery of new therapeutic targets and the repurposing of existing drugs with unprecedented precision.
Looking forward, the JAX team plans to refine the therapeutic approach and explore combination treatments involving KDM4 inhibitors with conventional or experimental agents. Promisingly, some KDM4-blocking compounds are already undergoing clinical trials for solid tumors, which may accelerate their translation into AML therapy. This strategic repurposing could expedite the initiation of early phase clinical studies, bypassing the lengthy drug development process from scratch.
The study highlights a critical biological insight—that cancer is not merely a genetic disease caused by mutations but also an epigenetic disease mediated by reversible gene silencing mechanisms. Unlocking this layer of regulation represents a frontier in precision medicine, offering hope for more effective and less toxic cancer treatments in the near future.
Moreover, the use of patient-derived cells in preclinical testing ensures that findings are highly relevant to human disease, increasing the likelihood that these therapeutic strategies will succeed in clinical settings. The selective targeting of leukemic cells while sparing normal hematopoietic cells is particularly encouraging, underscoring the potential for improved patient outcomes with fewer adverse effects.
In summary, this research from The Jackson Laboratory ushers in a novel therapeutic avenue that reactivates silenced tumor suppressor genes via epigenetic modulation. By harnessing cutting-edge molecular tools and repurposing existing pharmacological inhibitors, it charts a promising path toward transforming AML treatment and exemplifies the power of integrating genomics, epigenetics, and innovative drug development.
Subject of Research: Animals
Article Title: Epigenetic reactivation of the tumor suppressor ZBTB7A by KDM4 inhibition in human acute myeloid leukemia
News Publication Date: 25-Feb-2026
Web References: http://dx.doi.org/10.1126/scitranslmed.ady2936
Image Credits: The Jackson Laboratory
Keywords: Leukemia, Myeloid leukemia, Cancer, Epigenetics, Tumor suppressor gene, ZBTB7A, KDM4 inhibition, CRISPR, FISHnCRISP, Differentiation therapy, Acute myeloid leukemia, Gene silencing
